Business Description
Scinai Immunotherapeutics Ltd. is an Israel-based biopharmaceutical company founded in 2003 and headquartered in Jerusalem, focused on creating treatments for infectious and autoimmune diseases. The company is advancing a pipeline of tiny antibody-based therapies, including a treatment for serious skin conditions such as pemphigus and toxic epidermal necrolysis, as well as COVID-19 antibody candidates developed in partnership with leading European research institutions. Alongside its drug development work, Scinai offers manufacturing and development services to other biotech companies through a dedicated platform built in collaboration with Recipharm Israel Ltd.
